The activity of Certis’ mildewicide Cyflamid (cyflufenamid) could be boosted in tough situations by adding a specific adjuvant being developed by the firm.
In trials the adjuvant has added around 5% control of mildew in high disease pressure situations, the firm’s Alan Horgan said.
“It helps give stronger curative activity. We’d see it being used in that situation or where you’ve got established disease and needed extra activity.”
The firm is hopeful the adjuvant will be registered in time for next season’s full launch of Cyflamid.